Drug Trial Radar · NCT04941339
A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
74
Planned (sponsor's estimate)
Start
Nov 21, 2018
Primary completion
Oct 2022
Study completion Oct 2022
Sponsor
- Lead sponsor
- Shanghai Miracogen Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
MRG002Drug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: DLT will be evaluated during the first treatment cycle (Day 1-28)
- Recommended Phase II Dose (RP2D)Time frame: Baseline to study completion (up to 6 months)
- Adverse Events (AEs)Time frame: Baseline to 49 days after the last dose of study treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.